GoAI
Get started
MediciNova, Inc. logo

MediciNova, Inc.

4875.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥222

+¥6.00 · +2.78%

Aug 24, 11:26 AM JST

4875.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Yuichi Iwaki
Listed since
Dec 28, 2007
Employees
6

Market position

Day range

Current ¥222

52-week range

Current ¥222

Open
¥217
Previous close
¥216
Volume
64.2K
1.89× average
Average volume
33.89K
Average daily volume
Market cap
10.93B JPY
Beta
0.62
Market reference 1
50-day average
¥213.7
+3.88% above average
200-day average
¥228.26
-2.74% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
37.01M USD
P/E (TTM)
-6.4×
P/B (TTM)
1.84×
P/S (TTM)
74.33×
EV / EBITDA
-2.83×
Earnings yield
-17.74%
Free cash flow yield
-14.51%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
42.39%
Operating margin
-1287.41%
Net margin
-1168.20%
Return on equity
-28.85%
Return on assets
-26.31%
Return on invested capital
-31.63%

Financial health

Debt / equity
0×
Current ratio
8.16×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends434%-903%-2240%-3577%Gross margin, FY2021: 99.91%Gross margin, FY2023: 97.97%Gross margin, FY2025: 2.67%Operating margin, FY2021: -253.02%Operating margin, FY2023: -990.03%Operating margin, FY2025: -3242.47%Net margin, FY2021: -251.00%Net margin, FY2023: -857.15%Net margin, FY2025: -2928.78%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 99.91%. Gross margin FY2023 97.97%. Gross margin FY2025 2.67%. Operating margin FY2021 -253.02%. Operating margin FY2023 -990.03%. Operating margin FY2025 -3242.47%. Net margin FY2021 -251.00%. Net margin FY2023 -857.15%. Net margin FY2025 -2928.78%.

Income trends

Revenue

409.66K USD-59.39%

Operating income

−13.28M USD-4.79%

Net income

−12M USD-8.58%
Income trends across reported periods5.92M USD−1.61M USD−9.14M USD−16.68M USDRevenue, FY2021: 4.04M USDRevenue, FY2023: 1.01M USDRevenue, FY2025: 409.66K USDOperating income, FY2021: −10.23M USDOperating income, FY2022: −14.79M USDOperating income, FY2023: −9.99M USDOperating income, FY2024: −12.68M USDOperating income, FY2025: −13.28M USDNet income, FY2021: −10.14M USDNet income, FY2022: −14.23M USDNet income, FY2023: −8.65M USDNet income, FY2024: −11.05M USDNet income, FY2025: −12M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.04M USD. Revenue FY2023 1.01M USD. Revenue FY2025 409.66K USD. Operating income FY2021 −10.23M USD. Operating income FY2022 −14.79M USD. Operating income FY2023 −9.99M USD. Operating income FY2024 −12.68M USD. Operating income FY2025 −13.28M USD. Net income FY2021 −10.14M USD. Net income FY2022 −14.23M USD. Net income FY2023 −8.65M USD. Net income FY2024 −11.05M USD. Net income FY2025 −12M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue409.66K USD—1.01M USD—4.04M USD
Cost of goods sold398.71K USD21.08K USD20.47K USD214.8K USD—
Gross profit10.95K USD−21.08K USD988.18K USD−214.8K USD4.04M USD
Research and development7.13M USD7.17M USD5.69M USD9.03M USD8.52M USD
Selling, general, and administrative6.16M USD5.48M USD5.29M USD5.55M USD5.72M USD
Operating expenses13.29M USD12.65M USD10.97M USD14.58M USD14.24M USD
Interest income1.3M USD1.67M USD1.85M USD818.74K USD143.76K USD
Depreciation and amortization193.78K USD21.08K USD20.47K USD214.8K USD26.17K USD
Operating income−13.28M USD−12.68M USD−9.99M USD−14.79M USD−10.23M USD
Net income−12M USD−11.05M USD−8.65M USD−14.23M USD−10.14M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+17.98%
11 comparable reports
Latest EPS result
-7.32
Estimate -10.3 · Beat by 28.95%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-6.22-11.51-16.81-22.1Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 19, 2025: actual -9.43, estimate -8.65, surprise -9.09%, Miss. Q2 2025, reported May 14, 2025: actual -9, estimate -21, surprise +57.14%, Beat. Q3 2025, reported Aug 14, 2025: actual -17.63, estimate -13.69, surprise -28.74%, Miss. Q4 2025, reported Nov 13, 2025: actual -13.31, estimate -17.75, surprise +25.00%, Beat. Q1 2026, reported Feb 20, 2026: actual -9.4, estimate -14.89, surprise +36.84%, Beat. Q2 2026, reported May 14, 2026: actual -7.94, estimate -13.17, surprise +39.72%, Beat. Q3 2026, reported Aug 13, 2026: actual -7.32, estimate -10.3, surprise +28.95%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -10.08, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates79.89M55.84M31.79M7.73MQ3 '25No estimateQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q3 2025, reported Aug 14, 2025: actual 19.44M JPY, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 13, 2025: actual 9.1M JPY, estimate 18.5M JPY, surprise -50.83%, Miss. Q1 2026, reported Feb 20, 2026: actual 23.66M JPY, estimate 23.8M JPY, surprise -0.57%, Miss. Q2 2026, reported May 14, 2026: actual 29.69M JPY, estimate 29.69M JPY, surprise +0.00%, Beat. Q3 2026, reported Aug 13, 2026: actual 74.65M JPY, estimate 12.17M JPY, surprise +513.34%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 11.93M JPY, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

2 institutions
B. Riley SecuritiesmaintainBuy

Corporate actions

Corporate action history

Stock split

Effective Nov 1, 2006

1:10

4875.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥7,008

-0.04%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,799

+0.61%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,990

+0.38%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,205

+0.08%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,862

+1.01%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,392.5

+0.23%

Continue in GoAI

Research 4875.T

research.disclaimer